

<u>PATENT</u> Docket No. <u>2026-4116US2</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Bukh, et al

Serial No.

09/084,691

Group Art Unit: 1648

Filed

May 26, 1998

Examiner: Zeman, M.

For

NUCLEOTIDE AND DEDUCED AMINO ACID SEQUENCES OF

THE ENVELOPE 1 AND CORE GENES OF ISOLATES OF

HEPATITIS C VIRUS AND THE USE OF REAGENTS DERIVED FROM THESE SEQUENCES IN DIAGNOSTIC METHODS AND

VACCINES

Commissioner for Patents Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. §1.821(f) OR §1.825(b)

By:

Sir:

I hereby certify that:

[] The paper Sequence Listing and computer readable form of the Sequence Listing submitted herewith are identical (37 C.F.R. §1.821(f)).

[X] The substitute paper Sequence Listing and substitute computer readable form of the Sequence Listing submitted herewith are identical. No new matter is included. (37 C.F.R. §1.825(b)).

Respectfully submitted,

MORGAN, & FINNEGAN, L.L.P.

Date: August 30, 2001

William S. Féiler

Registration No. 26,728

CORRESPONDENCE ADDRESS:

MORGAN & FINNEGAN, L.L.P.

345 Park Avenue

New York, New York 10154-0053

(212) 758-4800 (Telephone)

(212) 751-6849 (Facsimile)

Docket No. <u>2026-4116US2</u>

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Bukh, et al

Serial No.

AUG 3 0 2001

09/084,691

Group Art Unit: 1648

Filed

May 26, 1998

Examiner: Zeman, M.

For

NUCLEOTIDE AND DEDUCED AMINO ACID SEQUENCES OF THE ENVELOPE 1 AND CORE GENES OF ISOLATES OF

HEPATITIS C VIRUS AND THE USE OF REAGENTS DERIVED FROM THESE SEQUENCES IN DIAGNOSTIC METHODS AND

VACCINES

Commissioner for Patents Washington, D.C. 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed August 1, 2001, applicant respectfully submits herewith a substitute paper sequence listing; Statement Under 37 CFR 1.825(b); and a substitute computer readable form of the Sequence Listing in replacement of the sequence listing now on file. No new matter is included.

The errors set forth in the Raw Sequence Listing Error Report have been corrected.

This response is timely filed. The Commissioner is hereby authorized to charge any additional fees which may be required by this paper or credit any overpayment to Deposit Account No. 13-4500. Order No. 2026-4116US2. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

By:

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Date: August 30, 2001

William S. Feiler

Registration No. 26,728

CORRESPONDENCE ADDRESS:

MORGAN & FINNEGAN, L.L.P. 345 Park Avenue New York, New York 10154-0053 (212) 758-4800 (Telephone) (212) 751-6849 (Facsimile)